Background-Calcineurin is a calcium-regulated phosphatase that plays a major role in cardiac hypertrophy. We previously described that alternative splicing of the calcineurin A␤ (CnA␤) gene generates the CnA␤1 isoform, with a unique C-terminal region that is different from the autoinhibitory domain present in all other CnA isoforms. In skeletal muscle, CnA␤1 is necessary for myoblast proliferation and stimulates regeneration, reducing fibrosis and accelerating the resolution of inflammation. Its role in the heart is currently unknown. Methods and Results-We generated transgenic mice overexpressing CnA␤1 in postnatal cardiomyocytes under the control of the ␣-myosin heavy chain promoter. In contrast to previous studies using an artificially truncated calcineurin, CnA␤1 overexpression did not induce cardiac hypertrophy. Moreover, transgenic mice showed improved cardiac function and reduced scar formation after myocardial infarction, with reduced neutrophil and macrophage infiltration and decreased expression of proinflammatory cytokines. Immunoprecipitation and Western blot analysis showed interaction of CnA␤1 with the mTOR complex 2 and activation of the Akt/SGK cardioprotective pathway in a PI3K-independent manner. In addition, gene expression profiling revealed that CnA␤1 activated the transcription factor ATF4 downstream of the Akt/mTOR pathway to promote the amino acid biosynthesis program, to reduce protein catabolism, and to induce the antifibrotic and antiinflammatory factor growth differentiation factor 15, which protects the heart through Akt activation. Conclusions-Calcineurin A␤1 shows a unique mode of action that improves cardiac function after myocardial infarction, activating different cardioprotective pathways without inducing maladaptive hypertrophy. These features make CnA␤1 an attractive candidate for the development of future therapeutic approaches. (Circulation. 2011;123:2838-2847.)
C alcineurin is a calcium-dependent serine/threonine phosphatase that regulates a wide variety of physiological and pathological processes. 1 Calcineurin links changes in intracellular calcium to gene transcription by dephosphorylating the transcription factor nuclear factor of activated T cells (NFAT), among others, and inducing its translocation to the nucleus. 1 It is composed of a catalytic subunit (CnA) and a regulatory subunit (CnB). Three different CnA isoforms are found in mammals: CnA␣ and CnA␤, which are ubiquitously expressed, and CnA␥, restricted to brain and testis. They share a common structure, including a phosphatase domain, CnB-binding region, calmodulin-binding region, and C-terminal autoinhibitory domain. In its inactive state, the catalytic site in CnA is blocked by this autoinhibitory domain. In response to raised intracellular calcium, CnB and calmodulin activate CnA by inducing a conformational change that displaces the autoinhibitory domain and exposes the catalytic site. Artificial removal of the autoinhibitory domain renders CnA constitutively active and results in full NFAT activation.
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In the heart, calcineurin participates in both cardiac development and disease. Calcineurin plays a central role in the development of maladaptive but not physiological hypertrophy. 2 Transgenic mice overexpressing an artificially truncated, constitutively active form of CnA␣ that lacks the autoinhibitory domain show strong cardiac hypertrophy and develop heart failure within the first weeks of age, a response phenocopied by overexpression of a constitutively active form of NFAT. 3 In contrast, knockout mice lacking the phosphatase domain of CnA␤, the main CnA isoform in the heart, show smaller hearts at baseline and reduced hypertrophy in response to pressure overload, angiotensin II, or isoproterenol. 4 Similarly, overexpression of the endogenous calcineurin inhibitor RCAN1 prevents cardiac growth and ameliorates heart function. 5 A protective role has also been proposed for calcineurin. Mice overexpressing constitutively active calcineurin show reduced apoptosis after ischemia/reperfusion, 6 whereas deletion of the phosphatase-encoding exon of CnA␤ results in increased cell death and reduced cardiac function. 7 However, the use of constitutively active calcineurin as a therapeutic agent for myocardial infarction is precluded by its strong induction of maladaptive cardiac hypertrophy. 3 We have recently reported that an alternative splicing form of CnA␤ (called CnA␤1) is induced by insulin-like growth factor 1 (IGF-1) and can, on its own, recapitulate the regenerative program elicited by IGF-1 in skeletal muscle. 8 This naturally occurring isoform lacks the autoinhibitory domain present in all other calcineurins, and contains instead a unique C-terminal domain that has no similarity to any other known protein. Here, we explore the effect of CnA␤1 overexpression in the heart.
Methods
A full Methods section can be found in the online-only Data Supplement.
Mice, Surgery, and Cardiac Function Analysis
␣-Myosin heavy chain (␣MHC)-CnA␤1 transgenic mice express CnA␤1 under the control of the ␣MHC promoter, which allows postmitotic cardiomyocyte-restricted expression. All operations were performed with the approval of the institutional ethics committee and the Home Office in the United Kingdom. Ten-week-old ␣MHC-CnA␤1 transgenic mice (nϭ27) and age-matched wild-type (WT) mice (nϭ27) were subjected to left coronary artery ligation, and echocardiography analysis was performed 7 and 28 days later. Two-dimensional and M-mode images were obtained at the level of the papillary muscles with a Vevo-770 imaging system (VisualSonics). Percent fractional area contraction (%FAC), a parameter of systolic function, was calculated from the left ventricular (LV) cross-sectional area: %FACϭ[(LVEDAϪLVESA)/LVEDA)ϫ100], where LVEDA and LVESA are LV end-diastolic area and end-systolic area. Both LVEDA and LVESA were measured by 2-dimensional trace at the papillary muscle level, and 3 beats were averaged for each measurement. Hemodynamic analysis was performed under isoflurane anesthesia. A 1.4-F microtipped pressure transducer (SPR-839, Millar Instruments) was inserted through the right carotid artery and advanced into the LV for measurement of LV pressure by a blinded operator. Hemodynamic parameters were calculated from the recorded data with commercial software (PVAN3.2, Millar Instruments). We calculated using the Glantz method. For rapamycin experiments, adult WT and transgenic mice (nϭ5 for each condition) were injected intraperitoneally daily for 4 days with 1 mg/kg rapamycin (Biomol) diluted in 0.2% (wt/vol) sodium carboxymethyl cellulose, 0.25% (vol/vol) polysorbate 80. Control mice received an equivalent intraperitoneal injection of solvent alone. Three hours after the last injection, mice were euthanized, hearts were excised, and the LV was snap-frozen.
RNA Extraction, Quantitative Real-Time Reverse-Transcribed Polymerase Chain Reaction, and Microarrays
Total RNA was extracted and quantitative real-time reverse-transcribed polymerase chain reaction was performed as described with off-theshelf Taqman probes (Applied Biosystems). 8, 9 Analysis was performed with the ⌬⌬Ct method with an 18S probe for normalization.
For microarray experiments, the different conditions were analyzed in triplicate using a MG_430A2.0 oligonucleotide-based microarray (Affymetrix). 8 Data were analyzed with Genespring 7.3 (Silicon Genetics). Each chip was normalized to the 50th percentile, and all samples were normalized to the WT uninjured samples. Those genes that had a raw expression of Ͼ10 in 4 of 6 conditions, a flag present or marginal in 6 of 18 samples, and a difference in normalized expression Ͻ1.7 or Ͼ1.7-fold were selected for each condition. Gene ontology analysis was performed as previously described. 8, 9 Western Blot Tissue lysates were separated in SDS-PAGE gels, transferred to nitrocellulose blots, and blocked with 5% nonfat dry milk in TBS (10 mmol/L Tris-HCl, pH 7.4, 150 mmol/L NaCl). Blots were incubated with primary antibodies overnight, followed by appropriate horseradish peroxidase-labeled secondary antibodies. Mouse monoclonal anti-CnA␤1 has been previously described. 8 Antibodies against phospho-PDK1, phospho-Akt, Akt, phospho-SGK, SGK, p-eIF2␣, eIF2␣, p-GCN2, and p-Bad were purchased from Cell Signaling. Anti-activating transcription factor (ATF4) was obtained from Abcam, and anti-NFATc1 was from Santa Cruz. Anti-Stag2 was a kind gift from Dr Jose Luis Barbero (Centro de Investigaciones Biológicas, Madrid, Spain).
Statistical Analysis
Cumulative mortality after MI was shown with Kaplan-Meier curves, and the log-rank test was used to assess statistical significance (PϽ0.05). Echocardiography data were analyzed for statistical significance with 2-tailed t tests. Hemodynamic data on WT and transgenic mice were compared by use of a nonparametric MannWhitney test. Gene expression in each region of the infarcted heart was analyzed independently and compared with the uninjured heart separately. To determine whether there was a significant difference between means of the experimental groups, gene expression data were analyzed with 2-way ANOVA, establishing the appropriate contrast of means, followed when necessary by the Bonferroni adjustment to make post hoc multiple comparisons. Standard diagnostics checks on the residuals from the fitted models showed no evidence of any failure of the assumption of normality and homogeneity of the residual variance. Note that samples for 7 and 28 days were taken from different mice, as were those from uninjured hearts. All data were analyzed with GraphPad Prism 5.0 (Graphpad Software Inc; www.graphpad.com) and the open-source statistical scripting language R version 2.11.0 (R Development Core Team; http:// www.R-project.org). Differences were considered to be statistically significant at PϽ0.05.
Results

Calcineurin A␤1 Does Not Induce Cardiac Hypertrophy
To examine the effect of CnA␤1 overexpression in the heart, we developed transgenic mice expressing CnA␤1 under the control of the ␣MHC promoter (␣MHC-CnA␤1 mice), which allows postnatal overexpression of CnA␤1 specifically in cardiac myocytes. Expression of both CnA␤1 mRNA and protein was induced in transgenic hearts compared with WT mice ( Figure 1A and 1B) . No significant differences in cardiac function, ratio of heart weight to body weight, or ventricular dilation were detected in transgenic mice ( Figure  1C through 1E and the Table) . In addition, adult cardiomyocytes isolated from ␣MHC-CnA␤1 mice displayed a cell surface area similar to those from WT mice ( Figure 1F ). Analysis of different heart failure and remodeling markers by quantitative real-time reverse-transcribed polymerase chain reaction showed no difference in brain natriuretic peptide, ␣-skeletal actin, or ␤MHC expression in ␣MHC-CnA␤1 mice ( Figure 1G ). Similarly, no changes were found for the fibroblast marker Thy1/CD90, collagen 1␣1, or lysyl oxidase, the enzyme responsible for collagen 1 and collagen 3 crosslinking ( Figure 1H ). Together, these results indicate that CnA␤1 overexpression in the heart does not induce cardiac hypertrophy, fibrosis, or remodeling, in contrast to the artificially truncated CnA form. 3 
Calcineurin A␤1 Improves Cardiac Function After Myocardial Infarction
To determine the effect of CnA␤1 on the response to cardiac injury, we induced myocardial infarction by permanently ligating the left coronary artery in both WT and transgenic mice. The ␣MHC-CnA␤1 mice showed improved survival after infarction compared with WT ( Figure 2A ), although the difference did not reach statistical significance. Transgenic mice had significantly reduced scar area and collagen deposition 28 days after injury ( Figure 2B and 2C ). In addition, whereas WT animals developed compensatory cardiomyocyte hypertrophy after infarction, transgenic cardiomyocytes showed significantly smaller cross-sectional area than WT cells ( Figure 2D ). Echocardiography confirmed significant dilation of the LV in WT mice from 7 days after infarction, accompanied by a decrease in systolic function as determined by %FAC (the Table) . In contrast, ␣MHC-CnA␤1 mice showed smaller LVESA and LVEDA and a significantly higher %FAC (1.5-fold). Similar results were found at 28 days after injury (Pϭ0.069). To confirm these results, we measured hemodynamic parameters using an invasive catheter 28 days after the surgery. Wild-type mice presented a significant increase in LV end-diastolic pressure, together with reduced contraction and relaxation capacities, as measured by dP/dTmax, dP/dTmin, and Tau g. Overexpression of CnA␤1 significantly prevented this deterioration of contractile and relaxation functions (the Table) . Together, these results show that CnA␤1 exerts a beneficial effect on the heart in the context of myocardial infarction. were measured in WT and transgenic mice with echocardiography and expressed as averageϮSE. E, Heart weight and body weight of WT and ␣MHC-CnA␤1 mice were determined at different ages and represented as averageϮSE ratio (mg/g). F, Cardiac myocytes were isolated from adult WT and ␣MHC-CnA␤1 hearts, and the averageϮSE cell area was quantified. G and H, mRNA expression of the indicated heart failure (G) and fibrosis (H) markers was determined by qRT-PCR and expressed as fold inductionϮSE over WT. ***PϽ0.0005.
Reduced Fibrosis and Accelerated Resolution of Inflammation in ␣-Myosin Heavy Chain-Calcineurin A␤1 Mice
We analyzed different fibrosis and inflammation parameters by quantitative real-time reverse-transcribed polymerase chain reaction in the infarct region, border zone, and myocardial area remote to the infarct. The cardiac fibroblast proliferation marker Thy1 10 showed a strong induction in the infarct region and border zone by 7 days after injury in WT mice ( Figure 3A ) that was significantly lower in ␣MHC-CnA␤1 animals. Both collagen 1␣1 and lysyl oxidase were strongly induced in the infarct region and border zones in WT mice, particularly 7 days after infarction when the scar is being formed (Figure 3B and 3C ). Calcineurin A␤1 overexpression decreased the expression of these markers in the infarct region 28 days after surgery. In the border zone, a significant reduction could already be seen by 7 days. Expression of fibrotic markers was also detected in the remote myocardial area, indicating the induction of interstitial fibrosis, although the expression was much lower than in the infarct region ( Figure 3A through 3C) . Transgenic mice showed lower levels of collagen 1␣1 and lysyl oxidase in this area as well ( Figure 3B and 3C) .
We next analyzed the expression of different leukocyte population markers and inflammatory mediators. To determine the presence of neutrophils and macrophages, we measured the expression of granzyme B and CD68, respectively. We observed robust expression of both markers at 7 days after injury in the infarct region and border zone of both WT and transgenic mice ( Figure 3D and 3E) . However, whereas expression of both granzyme B and CD68 was almost normalized in the border zone at 28 days in both groups, elevated expression persisted in the infarct region in WT mice. Notably, levels of these markers were significantly lower in the infarct region of transgenic mice, suggesting a faster resolution of inflammation in these mice compared with WT. Similarly, we observed a strong induction of the proinflammatory cytokine interleukin-6 in the infarct region and border zone of WT and transgenic mice 7 days after injury ( Figure 3F ). Whereas elevated interleukin-6 levels persisted at 28 days after injury in WT mice, ␣MHC-CnA␤1 hearts showed significantly lower interleukin-6 expression. Collectively, these results indicate that CnA␤1 decreases fibrosis and accelerates the resolution of inflammation after myocardial infarction.
Transcription Profile of Wild-Type and Transgenic Mice After Myocardial Infarction
To gain insight into the molecular mechanisms underlying the beneficial effects of CnA␤1, we analyzed the transcription profile of uninjured LV samples and myocardial samples from the area remote to the infarct 7 and 28 days after injury using oligonucleotide microarrays. As expected, we observed an increase in extracellular matrix and inflammation genes in WT mice after infarction, together with a decrease in mitochondrial metabolism genes (for a detailed explanation, please see the Results section, Figure I , and Tables I through XX in the online-only Data Supplement).
In this context, we looked for genes that showed differential expression (Ͼ1.7-fold) between WT and transgenic mice at each time point. In the absence of injury, ␣MHC-CnA␤1 mice showed decreased expression of genes involved in caspase activation and the response to stress (Tables XXIII Figure 2 . Calcineurin A␤1 (CnA␤1) reduces cardiac scar fibrosis after myocardial infarction. A, Myocardial infarction (MI) was induced by permanent ligation of the left coronary artery in wild-type (WT) and transgenic mice, and survival was determined over a 28-day period. B and C, Infarcted hearts were isolated 28 days after surgery, processed for histological analysis, and stained with Sirius red for determination of collagen content. Barϭ100 m. Scar area (C) was quantified and expressed as percentage over totalϮSE area. *PϽ0.05. D, Cardiomyocyte cross-sectional area (CSA) was quantified in uninjured and infarcted mice 28 days after injury and expressed as fold inductionϮSE over uninjured WT mice. *PϽ0.05, infarcted vs uninjured; #PϽ0.05, ␣-myosin heavy chain (␣MHC)-CnA␤1 vs WT. Reduced expression of fibrosis and inflammation markers in ␣-myosin heavy chaincalcineurin A␤1 (␣MHC-CnA␤1) mice. A through H, Expression of different fibrosis and inflammation markers was analyzed by quantitative reverse-transcribed polymerase chain reaction in myocardial samples from the infarct region (Infarct), infarct border zone (Border), and area remote to the infarct (Remote) 7 and 28 days after infarction. A, Fibroblast proliferation marker Thy1; B, collagen 1a1 (Col1a1); C, lysyl oxidase (Lox), which crosslinks collagen I and III fibers; D, neutrophil marker granzyme B (Gzmb); E, macrophage marker CD68; F, proinflammatory cytokine interleukin-6 (IL-6). Results are expressed as fold inductionϮSE over the wild-type (WT) uninjured values. *PϽ0.05, WT uninjured vs WT infarcted; #PϽ0.05, WT vs ␣MHC-CnA␤1 for each experimental condition (nϭ3 to 6). Each region in the infarcted heart was analyzed independently and compared with the uninjured heart separately.
and XXIV in the online-only Data Supplement) but no clear pattern among the upregulated genes (Tables XXI and XXII in the online-only Data Supplement). Seven days after infarction, we found a robust increase in ATF4 targets, amino acid biosynthesis, and cyclin D2-associated processes in ␣MHC-CnA␤1 mice (Tables XXVII and XXVIII in the online-only Data Supplement), together with reduced expression of genes involved in cell proliferation, amino acid catabolism, and fatty acid metabolism (Tables XXXI and XXXII, Figure II , and the Results section in the online-only Data Supplement). Four weeks after infarction, the upregulation of amino acid biosynthesis genes persisted (Tables XXXV and XXXVI in the online-only Data Supplement) and was accompanied by a decrease in genes involved in rhythmic processes (Tables XXXIX and XL in the online-only Data Supplement). Together, these results suggest that CnA␤1 partially prevents the molecular processes associated with myocardial infarction and that it specifically targets the amino acid biosynthesis program.
Calcineurin A␤1 Activates Activating Transcription Factor 4
To validate the microarray results, we first analyzed ATF4 mRNA expression by quantitative real-time reverse-transcribed polymerase chain reaction and found that it was significantly induced in the remote area of ␣MHC-CnA␤1 hearts compared with WT at 7 days after injury ( Figure 4A ). Because ATF4 expression is controlled mainly at the translational level, 11 we performed Western blot analysis and observed an upregulation of ATF4 protein in myocardial samples from transgenic animals ( Figure 4B ). Immunofluorescence analysis at 7 days after injury showed that ATF4 was expressed principally by cardiomyocytes, although it could also be detected in some nonmuscle cells ( Figure 4C ). Quantitative real-time reverse-transcribed polymerase chain reaction analysis of the ATF4 targets ATF5 and asparagine synthetase confirmed a strong upregulation of both molecules in the remote area of ␣MHC-CnA␤1 mice 7 days after injury and in uninjured hearts ( Figure 4D and 4E ). In addition, we observed that expression of the cardioprotective factor growth differentiation factor 15, which was also identified in the arrays (Table XXV in the online-only Data Supplement) and is an ATF4 target, 12 was significantly increased in the remote area of transgenic mice 7 days after infarction ( Figure  4F ). This induction was also seen in the infarct region and in uninjured hearts.
Calcineurin A␤1 Activates Protective Signaling Pathways in the Heart
To identify the signaling pathways mediating the protective action of CnA␤1, we compared the proteomic profile of WT and transgenic hearts using antibody microarrays. Calcineurin A␤1-induced changes in protein phosphorylation and expression were similar in uninjured samples and remote myocardium 7 days after injury (Pϭ0.0015, nonparametric correlation). In both uninjured and infarcted hearts, CnA␤1 activated components of the Akt pathway (Tables XLI through XLIII in the online-only Data Supplement), including PRAS40 and mTOR. Western blot analysis revealed increased phosphorylation of PDK1, Akt, SGK, PRAS40, and mTOR in response to CnA␤1 overexpression, confirming the microarray results, and inactivation of the proapoptotic protein Bad ( Figure 5A ). In addition, transfection of WT neonatal cardiomyocytes with CnA␤1 siRNA reduced Akt phosphorylation ( Figure 5B ), indicating that CnA␤1 is both necessary and sufficient for Akt activation. Only a modest increase in the amount of nuclear NFAT was detected in ␣MHC-CnA␤1 mice ( Figure  5C ). Similarly, we found no significant differences in CnA␣, CnA␤2, CnB, or calmodulin expression between WT and ␣MHC-CnA␤1 mice ( Figure IIIB , IIIC, and IIIE in the online-only Data Supplement). Moreover, we found no significant increase in calcineurin enzymatic activity or in the expression of the NFAT-regulated gene Rcan1/Mcip1/Dscr1 ( Figure IIID and IIIF in the online-only Data Supplement), suggesting that the NFAT signaling pathway was not activated in ␣MHC-CnA␤1 hearts.
To determine how the Akt pathway is activated by CnA␤1, we used HEK293T cells, which can be efficiently transfected. Overexpression of CnA␤1 led to a mild increase in Akt activation ( Figure 5D ) compared with both CnA␤2 and a truncated constitutively active CnA␤ form lacking the autoinhibitory and unique domains (CnA␤*). Importantly, inhibition of PI3K activity with LY294002 blocked Akt activation in all conditions except in the presence of CnA␤1, suggesting that CnA␤1 was activating the Akt pathway below PI3K. To explore whether CnA␤1 could interact with mTOR complex 2 (mTORC2), we transfected HEK293T cells with green fluorescent protein (GFP)-containing chimeras linked to either full CnA␤1 and CnA␤2 proteins ( Figure 6A ) or their respective C-terminal domains ( Figure 6B ). Both Rictor and -C ter ; B) , or to CnA␤2 autoinhibitory domain (GFP-CnA␤2-C ter ; B). Proteins interacting with Rictor or GFP-containing chimeras were detected by immunoprecipitation (IP) followed by Western blot. C, Rictor was immunoprecipitated from wild-type (WT) heart lysates, and CnA␤1 was detected by Western blot. D, Interaction between CnA␤1 and CnB was detected in WT and ␣-myosin heavy chain (␣MHC)-CnA␤1 hearts by IP followed by Western blot. mTOR, components of the mTORC2, strongly coimmunoprecipitated with GFP-CnA␤1 ( Figure 6A ), whereas only a weak band could be seen in the GFP-CnA␤2 lane. Furthermore, a GFP chimera linked to the C-terminal domain of CnA␤1 was sufficient to coimmunoprecipitate Rictor and mTOR ( Figure 6B ), in contrast to a construct carrying GFP linked to the autoinhibitory domain of CnA␤2, indicating that the unique C-terminal domain of CnA␤1 is both necessary and sufficient to interact with mTORC2. We confirmed the interaction between endogenous CnA␤1 and Rictor in vivo by immunoprecipitation in WT uninjured hearts ( Figure 6C) . Moreover, we found that both endogenous and overexpressed CnA␤1 interacts with CnB ( Figure 6A and 6D) , suggesting that both molecules exist as a dimer.
Although ATF4 was initially described as a stress-inducible factor, 13 it can also be activated by the PI3K/Akt/mTOR pathway in response to growth factors and cytokines. 14,15 Whereas we did not detect activation of stress response mediators eIF2␣ or eIF2␣ kinases PKR, PERK, or Gcn2 in ␣MHC-CnA␤1 mice (not shown), inhibition of mTORC1 activity with rapamycin reduced ATF4 induction by CnA␤1 ( Figure 7A) . Similarly, rapamycin partially prevented the induction of ATF4 targets asparagine synthetase, ATF5, and growth differentiation factor 15 down to 50% without affecting CnA␤1 or CnA␤2 expression Figure 7 . Induction of activating transcription factor (ATF4) by calcineurin A␤1 (CnA␤1) is mediated by mTOR. A, Wild-type (WT) and ␣-myosin heavy chain (␣MHC)-CnA␤1 mice were injected intraperitoneally daily with 1 mg/kg rapamycin (ϩ) or vehicle (Ϫ) for 4 days. Mice were euthanized 3 hours after the last injection, and the expression of ATF4 in the left ventricle was analyzed by Western blot. B through F, Expression of CnA␤1, CnA␤2, and the ATF4 targets asparagine synthetase (Asns), ATF5, and growth differentiation factor 15 (GDF15) was analyzed in these hearts by quantitative reverse-transcribed polymerase chain reaction. Results are expressed as fold inductionϮSE over uninjured WT. *PϽ0.05, ***PϽ0.0005, WT vs ␣MHC-CnA␤1; #PϽ0.05, rapamycin vs vehicle (control; nϭ4). G, Neonatal cardiomyocytes from WT and ␣MHC-CnA␤1 mice were exposed to 1% oxygen in the presence of 15 mol/L LY294002, 1 mol/L rapamycin, or 1:1000 dimethyl sulfoxide (control), and cell death was quantified by measuring the release of lactate dehydrogenase (LDH) to the culture medium. Results are expressed as fold inductionϮSE over normoxic untreated cells for each mouse line. *PϽ0.05, *PϽ0.005, ***PϽ0.0005, hypoxia vs normoxia; #PϽ0.05, ###PϽ0.0005, WT vs ␣MHC-CnA␤1 (nϭ4 to 16). H, Schematic summarizing the activation of cardioprotective signaling by CnA␤1 in the heart.
( Figure 7B through 7F) . To explore whether activation of the mTOR pathway was also mediating the cardioprotective action of CnA␤1, we studied the response of neonatal cardiomyocytes to hypoxia. Exposure of WT cardiomyocytes to 1% oxygen decreased cell viability, as shown by an increase in lactate dehydrogenase released to the culture medium, whereas transgenic cells were unaffected ( Figure 7G ). Although inhibition of PI3K activity with LY294002 had no effect on the protective action of CnA␤1, blockade of mTOR with rapamycin resulted in similar loss of cell viability in WT and transgenic cardiomyocytes.
Discussion
We report here that the physiological, naturally occurring calcineurin isoform CnA␤1 improves cardiac function after myocardial infarction, reducing inflammation and scar formation. Functional improvement is already evident 1 week after infarction, suggesting that CnA␤1 may have a cardioprotective action. This cardioprotective effect is reproduced in culture, where CnA␤1 protects cardiomyocytes from cell death induced by hypoxia. In the heart, PDK1 and Akt mediate the beneficial effects of ischemic preconditioning, 16, 17 and SGK mediates the cardioprotective action of IGF-1. 18, 19 We had previously reported that CnA␤1 is necessary for the activation of the Akt pathway in proliferating myoblasts. 8 Here, we show that CnA␤1 is not only necessary but also sufficient to elicit this protective mechanism. Our data suggest that both mTORC2 and PDK1 are involved in the activation of the Akt/SGK pathway by CnA␤1 because both Ser473 and Thr308 in Akt are more phosphorylated in CnA␤1-overexpressing mice. Activation of Akt by CnA␤1 is insensitive to PI3K inhibition, suggesting that CnA␤1 enters the Akt pathway below PI3K. After exploring different components of the pathway, we found that CnA␤1 interacts with the mTORC2. Moreover we demonstrated that the unique C-terminal domain of CnA␤1 mediates this interaction and is necessary for Akt activation by CnA␤1. Neither CnA␤2 nor a truncated constitutively active CnA␤ with no autoinhibitory or unique domains shows this ability, indicating that the alternative C-terminal domain confers unique properties to CnA␤1 that are not shared by other calcineurin isoforms. Although chronic strong activation of Akt induces maladaptive cardiac hypertrophy, 20 we see no hypertrophy in ␣MHC-CnA␤1 mice. It is likely that the levels of Akt activation in these mice are below those required for the induction of cardiac hypertrophy, as shown for other mouse models in which mild chronic Akt activation promotes survival without inducing hypertrophy. 21 The protective activity of CnA␤1 is reminiscent of the IGF-1Ea isoform, which improves cardiac function by activating the PDK1/SGK axis with no cardiac hypertrophy. 18 IGF-1Ea has antiinflammatory and antifibrotic properties that were also mimicked by CnA␤1, which decreased the presence of neutrophils and macrophages and the expression of inflammatory cytokines and fibrotic markers and reduced scar formation. The antiinflammatory and antifibrotic actions of CnA␤1 may be mediated at least in part by growth differentiation factor 15, a member of the transforming growth factor-␤ family, which inhibits macrophage activation. Growth differentiation factor 15 is produced by cardiomyocytes in both hypertrophic and ischemic hearts 22, 23 and has a protective antiapoptotic action mediated by Akt that limits heart damage after infarction, reduces scar formation, and improves cardiac function. 23 In addition, it attenuates cardiac hypertrophy, limits ventricular dilation, and reduces heart failure in different mouse models. 22 Our data identify ATF4 as a potential mediator of the cardioprotective actions of CnA␤1. It protects the cell from stress by activating the amino acid biosynthesis program and inducing expression of antioxidant genes such as glutathione 24 and protective growth factors like growth differentiation factor 15. 12, 25 Activating transcription factor is controlled principally at the translational level in response to endoplasmic reticulum stress or amino acid starvation. 13, 25 However, we observed no activation of the associated stress-induced kinases PERK, PRK, or Gcn2; no phosphorylation of eIF2␣; and no induction of a gene expression pattern indicative of endoplasmic reticulum stress in CnA␤1-overexpressing mice. Alternatively, ATF4 can be activated by anabolic stimuli such as insulin, IGF-1, and fetal serum through the mTORC1 to enhance amino acid uptake and biosynthesis and to decrease protein catabolism. 14 We found that induction of ATF4 and its targets by CnA␤1 was abolished by rapamycin injection, suggesting that CnA␤1 activates ATF4 through mTORC1 independently of the endoplasmic reticulum stress and amino acid starvation response. Given that CnA␤1 expression is induced by IGF-1, 8 it is reasonable that both molecules share a common pathway for the activation of amino acid anabolism through ATF4, as they do for the blockade of protein catabolism and muscle atrophy through FoxO inhibition. 8 Collectively, our data support a role for ATF4 and amino acid biosynthesis in cardioprotection and the activation of this transcription factor through Akt independently of endoplasmic reticulum stress.
Conclusions
Activation of CnA␤1 in the heart elicits a cardioprotective pathway that contributes to decreased scar formation and to improved cardiac function after myocardial infarction. Although some of these actions are shared by the truncated CnA, 6, 26 artificial CnA activation has the major disadvantage of rapidly inducing cardiac hypertrophy and heart failure, 3 making it unsuitable for therapeutic purposes. In contrast, the naturally active CnA␤1 isoform protects the myocardium from the detrimental effects of ischemic injury without inducing hypertrophy. These features make CnA␤1 an attractive candidate for the development of future therapeutic approaches.
